Actively Recruiting
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
Led by University of Aarhus · Updated on 2026-03-13
617
Participants Needed
6
Research Sites
130 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
G
Gødstrup Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) - called "HCC surveillance" - offered to selected patients with chronic liver disease can reduce HCC-related mortality by facilitating earlier detection of HCC. The screening procedure consists of two tests: an ultrasound examination of the liver and a blood sample to measure alpha-fetoprotein. Patients who screen positive on either examination will be offered standard work-up for HCC, typically beginning with a CT-scan. In the study HCC surveillance will be offered to all patients with compensated non-viral cirrhosis residing in the Central Denmark Region, one of five administrative regions of Denmark. The study aims to determine the efficacy of HCC surveillance in reducing HCC-related mortality by comparing HCC-related mortality between the Central Denmark Region and the other four Danish regions, where HCC surveillance is not offered.
CONDITIONS
Official Title
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Cirrhosis
-
No history of chronic hepatitis B or C
-
Compensated cirrhosis defined as:
- No recent variceal bleeding, no uncontrolled ascites, no clinically apparent hepatic encephalopathy, and Child-Pugh score ≤ 8
-
Age 40-79 years
-
Expected remaining life expectancy ≥ 1 year
-
Not already in follow-up after treatment for HCC
-
No clinical suspicion of HCC
You will not qualify if you...
-
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Aarhus University Hospital
Aarhus, Central Jutland, Denmark, 8200
Actively Recruiting
2
Regional Hospital Gødstrup
Herning, Central Jutland, Denmark, 7400
Actively Recruiting
3
Horsens Regional Hospital
Horsens, Central Jutland, Denmark, 8700
Actively Recruiting
4
Randers Regional Hospital
Randers, Central Jutland, Denmark, 8930
Actively Recruiting
5
Silkeborg Regional Hospital
Silkeborg, Central Jutland, Denmark, 8600
Actively Recruiting
6
Viborg Regional Hospital
Viborg, Central Jutland, Denmark, 8800
Actively Recruiting
Research Team
P
Peter Jepsen, Professor, MD, PhD
CONTACT
M
Morten Hallengreen, PhD student
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here